Ignite Creation Date:
2024-05-05 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00367913
Status:
COMPLETED
Last Update Posted:
2006-08-23
First Post:
2006-08-21
Brief Title:
Clarithromycin v Ciprofloxacin Added to Rifampicin Ethambutol for Opportunist Mycobacterial Pulmonary Disease
Sponsor:
British Thoracic Society
Organization:
British Thoracic Society
Study Overview
Official Title:
Treatment of Pulmonary Disease Caused by MAIS MXenopi or MMalmoense A Comparison of Two Triple Drug Regimens and an Assessment of the Value of Immunotherapy With MVaccae
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To date key drugs in the treatment of MAIS Mmalmoense and Mxenopi Opportunist Mycobacteria have been rifampicin and ethambutol Clarithromycin and Ciprofloxacin are active in vitro against these species of mycobacteria The primary aim of this study was to compare these to agents as supplements to rifampicin and ethambutol A secondary aim was to assess the vale of immunotherapy with Mvaccae
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None